• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure

    4/9/26 4:05:32 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care
    Get the next $SYK alert in real time by email
    8-K/A
    STRYKER CORPtrue0000310764 0000310764 2026-03-11 2026-03-11 0000310764 syk:SeniorUnsecuredNotesThreePointThreeSevenFiveDue2032Member 2026-03-11 2026-03-11 0000310764 syk:SeniorUnsecuredNotesThreePointSixTwoFiveDue2036Member 2026-03-11 2026-03-11 0000310764 us-gaap:CommonStockMember 2026-03-11 2026-03-11 0000310764 syk:SeniorUnsecuredNotesTwoPointOneTwoFiveDue2027Member 2026-03-11 2026-03-11 0000310764 syk:SeniorUnsecuredNotesThreePointThreeSevenFiveDue2028Member 2026-03-11 2026-03-11 0000310764 syk:SeniorUnsecuredNotesZeroPointSevenFiveZeroDue2029Member 2026-03-11 2026-03-11 0000310764 syk:SeniorUnsecuredNotesTwoPointSixTwoFiveDue2030Member 2026-03-11 2026-03-11 0000310764 syk:SeniorUnsecuredNotesOnePointZeroZeroZeroDue2031Member 2026-03-11 2026-03-11 0000310764 syk:March112026IncidentMember 2026-03-11 2026-03-11
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
     
    FORM
    8-K/A
    (Amendment No.1)
     
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): March 11, 2026
     
     
     
    LOGO
    Stryker Corporation
    (Exact name of Registrant as Specified in Its Charter)
     
     
     
    Michigan
     
    001-13149
     
    38-1239739
    (State or Other Jurisdiction
    of Incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)
     
    1941 Stryker Way
    Portage, Michigan
     
    49002
    (Address of Principal Executive Offices)
     
    (Zip Code)
    Registrant’s Telephone Number, Including Area Code: (269)
    385-2600
    (Former Name or Former Address, if Changed Since Last Report)
     
     
    Check the appropriate box below if the Form
    8-K
    filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule
    14a-12
    under the Exchange Act (17 CFR
    240.14a-12)
     
    ☐
    Pre-commencement
    communications pursuant to Rule
    14d-2(b)
    under the Exchange Act (17 CFR
    240.14d-2(b))
     
    ☐
    Pre-commencement
    communications pursuant to Rule
    13e-4(c)
    under the Exchange Act (17 CFR
    240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
      
    Trading
    Symbol(s)
      
    Name of each exchange
    on which registered
    Common Stock, $.10 Par Value    SYK    New York Stock Exchange
    2.125% Notes due 2027    SYK27    New York Stock Exchange
    3.375% Notes due 2028    SYK28    New York Stock Exchange
    0.750% Notes due 2029    SYK29    New York Stock Exchange
    2.625% Notes due 2030    SYK30    New York Stock Exchange
    1.000% Notes due 2031    SYK31    New York Stock Exchange
    3.375% Notes due 2032    SYK32    New York Stock Exchange
    3.625% Notes due 2036    SYK36    New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
    12b-2
    of the Securities Exchange Act of 1934
    (§ 240.12b-2
    of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     
     

    Explanatory Note
    This Amendment No.1 (the “Amendment”) amends the Current Report on Form
    8-K
    filed by Stryker Corporation (the “Company”) with the Securities and Exchange Commission (the “SEC”) on March 11, 2026 (the March 11, 2026,
    8-K
    referred hereinto as the “Original Report”).
     
    Item 1.05
    Material Cybersecurity Incidents.
    As previously disclosed in the Original Report and as further reported on two Item 7.01 Current Reports on Form
    8-K,
    furnished to the SEC on March 12, 2026, and March 23, 2026 respectively, on March 11, 2026, the Company identified a cybersecurity incident, which when it occurred, caused disruptions to the Company’s business operations. Since then, the Company has worked diligently, together with third-party experts and law enforcement, to contain and neutralize the impact of the incident and restore operations. The Company’s investigation of the incident remains ongoing.
    Based on the information currently available to the Company, and assessment of both quantitative and qualitative factors that emerged in the weeks following the incident, the Company has determined that the incident had a material impact on its operations, with resulting impact to the Company’s financial results for the first quarter of 2026. In reaching this determination, the Company considered factors including the scope and duration of the operational disruption, the systems affected and the potential for customer, regulatory and other impacts.
    The Company believes that the incident has not had, and is not reasonably likely to have, a material impact on the Company’s 2026 full-year guidance.
    As of the date of this Amendment, the Company is fully operational across its global manufacturing network and commercial, ordering and distribution systems have been restored.
     
    Item 7.01
    Regulation FD Disclosure.
    The Company is scheduled to report earnings for its first quarter of fiscal year 2026 on April 30, 2026, where it will discuss its financial results and components of its full-year guidance in further detail.
    The information furnished under Item 7.01 of this Amendment, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

    Caution Concerning Forward-Looking Statements
    This Current Report on Form
    8-K
    contains forward-looking statements subject to the safe harbor protection provided by Section 27A of the Securities Act of 1933, Section 21E of the Exchange Act, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements regarding the Company’s current beliefs regarding the extent of the cybersecurity incident and the results or findings of the Company’s investigation thereof; the Company’s ability to contain and/or mitigate the incident; the disruption to our business or operations; and the potential impact on the Company’s reputation, financial condition and results of operations. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause actual results to differ materially from expectations as of the date of this filing. Factors that could cause actual results to differ materially from those indicated in the forward-looking statements include, but are not limited to, any impairment of the integrity of the Company’s systems or data; delays or difficulties in restoring the Company’s systems and data; the Company’s continued ability to use alternatives to its systems, to the extent needed; the Company’s ability to process information it collected while using alternatives to its systems and the integrity of that information; the adequacy of processes during the period of disruption of the Company’s systems; the results of the Company’s analysis of the scope and details of the cybersecurity incident; the unauthorized release of any of the Company’s data, including third party data held by the Company, or the use of any such data for any fraudulent purposes; potential adverse impact of the incident on the Company’s results of operations, including revenue, operating income and cash flows from operations, and on its financial condition, including liquidity; diversion of management’s attention from operations of the Company to address the cybersecurity incident; the outcome of litigation or potential litigation related to the cybersecurity incident; potential adverse effects on relationships with customers, suppliers, patients and other third parties as a result of the cybersecurity incident; reputational risk related to the cybersecurity incident; regulatory scrutiny as a result of the cybersecurity incident; and other risks listed or described from time to time in our filings with the SEC, including our Annual Report on Form
    10-K
    and Quarterly Reports on Form
    10-Q
    that we have filed or will file hereafter. Except as required by applicable law, we disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.

    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
       
    STRYKER CORPORATION
        (Registrant)
    Dated: April 9, 2026     By:   /s/ Tina S. French
        Name:   Tina S. French
        Title:   Corporate Secretary
    Get the next $SYK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SYK

    DatePrice TargetRatingAnalyst
    4/13/2026$410.00Outperform
    Leerink Partners
    2/20/2026Outperform
    William Blair
    1/27/2026$387.00Hold
    TD Cowen
    1/6/2026$418.00Mkt Perform → Outperform
    Raymond James
    12/19/2025$440.00Mkt Perform → Mkt Outperform
    Citizens JMP
    9/18/2025$420.00Neutral
    Rothschild & Co Redburn
    2/26/2025$450.00Buy
    Citigroup
    12/2/2024$370.00 → $445.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $SYK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Stryker with a new price target

    Leerink Partners initiated coverage of Stryker with a rating of Outperform and set a new price target of $410.00

    4/13/26 9:01:23 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    William Blair initiated coverage on Stryker

    William Blair initiated coverage of Stryker with a rating of Outperform

    2/20/26 8:25:36 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    TD Cowen resumed coverage on Stryker with a new price target

    TD Cowen resumed coverage of Stryker with a rating of Hold and set a new price target of $387.00

    1/27/26 8:50:06 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures

    PORTAGE, Mich., June 2, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of its TPX HD, a premium small bone power tool designed to support performance, control and ergonomics in a wide range of challenging orthopaedic procedures such as total joint revisions, minimally invasive surgery and oral maxillofacial procedures. "Revision procedures are some of the most demanding cases surgeons face, especially when metal cutting is involved," said Mike Carlin, president of Stryker's Ortho Tech division. "TPX HD was designed with tho

    6/2/26 9:03:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker Launches Pangea Plating System and Completes First Case in Europe

    Stryker (NYSE:SYK), a global leader in medical technologies, announced today the European launch of its Pangea Plating System, a plating platform for the treatment of a wide range of fracture patterns. Prof. Alex Trompeter, design surgeon and orthopaedic trauma surgeon, along with his team at St. George's University Hospital in London, completed the first clinical case in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525326817/en/Stryker's Pangea Plating System brings together thoughtfully designed plates and a streamlined instrumentation set, giving surgeons practical options when treating a range of fractures. "Pan

    5/26/26 2:10:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem

    Three companies with strong roots in the state are revolutionizing the treatment of cardiovascular disease through hydraulic lithotripsy technology BioStar Capital, a venture capital firm focused on transformative medical technologies, has announced a landmark pre-FDA exit of Amplitude Vascular Systems, Inc. (AVS), a medical technology company that created a next-generation hydraulic intravascular lithotripsy (IVL) platform to treat calcified peripheral arterial disease. Upon acquiring AVS for up to $835 million, Stryker (NYSE:SYK), a global leader in medical technologies, called the deal a milestone in the expansion of its peripheral vascular portfolio. All three companies have close t

    5/19/26 5:30:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)

    4 - STRYKER CORP (0000310764) (Issuer)

    6/2/26 4:24:03 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)

    4 - STRYKER CORP (0000310764) (Issuer)

    5/29/26 4:59:21 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)

    4 - STRYKER CORP (0000310764) (Issuer)

    5/28/26 5:22:36 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    SEC Filings

    View All

    SEC Form SD filed by Stryker Corporation

    SD - STRYKER CORP (0000310764) (Filer)

    5/22/26 10:27:54 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Stryker Corporation

    8-K - STRYKER CORP (0000310764) (Filer)

    5/20/26 4:21:47 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Stryker Corporation

    10-Q - STRYKER CORP (0000310764) (Filer)

    5/11/26 11:10:33 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Financials

    Live finance-specific insights

    View All

    Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio

    Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease. "This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease," said Kevin Lobo, Chair and CEO, Stryker. "By integrating AVS's innovative CO₂-generated pressure wave technology with Stryker's scale and resources, we are well-positioned to deliver solutions that support p

    5/7/26 4:05:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker declares an $0.88 per share quarterly dividend

    Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the close of business on June 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 m

    5/7/26 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker reports first quarter 2026 operating results

    Portage, Michigan, April 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2026: First Quarter Results Reported net sales increased 2.6% to $6.0 billionOrganic net sales increased 2.4%Reported operating income margin of 15.5%Adjusted operating income margin(1) contracted 180 bps to 21.1%Reported EPS increased 14.2% to $1.93 Adjusted EPS(1) decreased 8.5% to $2.60  First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        5.0        %         1.4        %         3.6        %         2.7        %         0.9        %Orthopaedics        

    4/30/26 4:05:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Leadership Updates

    Live Leadership Updates

    View All

    GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

    GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

    3/17/26 9:00:00 AM ET
    $GEHC
    $SYK
    Medical Electronics
    Health Care
    Medical/Dental Instruments

    Stryker showcases continued innovation across orthopaedics at AAOS 2026 Annual Meeting

    Evolving technologies and offerings reinforce commitment to shaping the future of orthopaedic care PORTAGE, Mich., March 3, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases its commitment to innovation across orthopaedic specialties with the introduction of the newest additions to the Triathlon® Total Knee System, the expanded Mako SmartRobotics™ portfolio and continued evolution of the power tool portfolio at the American Academy of Orthopaedic Surgeons' (AAOS) 2026 Annual Meeting in New Orleans. Triathlon Gold: Building on the legacy

    3/3/26 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

    Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev

    3/11/25 8:03:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/12/24 10:18:54 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/14/23 12:37:55 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/10/23 9:18:16 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care